Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa
- 1 May 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (5) , 1766-1771
- https://doi.org/10.1128/aac.01410-08
Abstract
The characterization of AmpC-type β-lactamases was performed in a collection of 32 clinical Pseudomonas aeruginosa isolates with intermediate susceptibility or resistance to imipenem and ceftazidime. Twenty-one out of those 32 isolates overexpressed AmpC β-lactamase, and the MICs of ceftazidime and imipenem were reduced after cloxacillin addition. Cloning and sequencing identified 10 AmpC β-lactamase variants. Reduced susceptibility to imipenem, ceftazidime, and cefepime was observed only with recombinant P. aeruginosa strains expressing an AmpC β-lactamase that had an alanine residue at position 105. The catalytic efficiencies ( k cat / K m ) of the AmpC variants possessing this residue were increased against oxyiminocephalosporins and imipenem. In addition, we show here that those AmpC variants constitute a favorable background for the in vitro selection of imipenem-resistant strains. This report identified a novel resistance mechanism that may contribute to imipenem resistance in P. aeruginosa .Keywords
This publication has 30 references indexed in Scilit:
- Contribution of extended-spectrum AmpC (ESAC) β-lactamases to carbapenem resistance in Escherichia coliFEMS Microbiology Letters, 2008
- Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa Isolates from Spanish HospitalsAntimicrobial Agents and Chemotherapy, 2007
- Extension of the hydrolysis spectrum of AmpC β-lactamase of Escherichia coli due to amino acid insertion in the H-10 helixJournal of Antimicrobial Chemotherapy, 2007
- Naturally Occurring Extended-Spectrum Cephalosporinases in Escherichia coliAntimicrobial Agents and Chemotherapy, 2006
- Interplay of Efflux System, ampC , and oprD Expression in Carbapenem Resistance of Pseudomonas aeruginosa Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2006
- Involvement of the MexXY-OprM Efflux System in Emergence of Cefepime Resistance in Clinical Strains of Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2006
- Metallo-β-Lactamases: the Quiet before the Storm?Clinical Microbiology Reviews, 2005
- Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC β-lactamase of a Serratia marcescens clinical isolateJournal of Antimicrobial Chemotherapy, 2005
- Inhibitor-Sensitive AmpC β-Lactamase Variant Produced by an Escherichia coli Clinical Isolate Resistant to Oxyiminocephalosporins and CephamycinsAntimicrobial Agents and Chemotherapy, 2004
- Mutational Replacement of Leu-293 in the Class C Enterobacter cloacae P99 β-Lactamase Confers Increased MIC of CefepimeAntimicrobial Agents and Chemotherapy, 2002